Cambridge Investment Research Advisors
TCRT icon

Cambridge Investment Research Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-95
Closed -$18K – 3158
2022
Q2 		$18K Buy
+95
New +$9.08K ﹤0.01% 3007
2020
Q4 		– Sell
-78
Closed -$29K – 2782
2020
Q3 		$29K Buy
+78
New +$34.5K ﹤0.01% 2477
2018
Q3 		– Sell
-325
Closed -$147K – 2301
2018
Q2 		$147K Sell
325
-10
-3% -$6.34K ﹤0.01% 2067
2018
Q1 		$197K Buy
335
+7
+2% +$4.36K ﹤0.01% 1970
2017
Q4 		$204K Buy
328
+2
+0.6% +$1.44K ﹤0.01% 1911
2017
Q3 		$300K Buy
326
+43
+15% +$38.2K ﹤0.01% 1552
2017
Q2 		$264K Buy
+283
New +$277K ﹤0.01% 1585
2016
Q4 		– Sell
-163
Closed -$138K – 1805
2016
Q3 		$138K Buy
163
+4
+3% +$3.21K ﹤0.01% 1633
2016
Q2 		$131K Sell
159
-2
-1% -$2.18K ﹤0.01% 1454
2016
Q1 		$179K Buy
161
+65
+68% +$66.5K ﹤0.01% 1423
2015
Q4 		$120K Sell
96
-4
-4% -$6.62K ﹤0.01% 1469
2015
Q3 		$135K Buy
+100
New +$165K ﹤0.01% 1328

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cambridge Investment Research Advisors's TCRT Position: Q3 2022 in Review

Cambridge Investment Research Advisors sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 95 shares — an estimated $18K sold.

Cambridge Investment Research Advisors first reported a position in TCRT in Q3 2015 and held it in 12 quarters. The position peaked at $300K in Q3 2017. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • Cambridge Investment Research Advisors reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 95 Alaunos Therapeutics shares in Q3 2022, an estimated $18K.
  • Cambridge Investment Research Advisors first reported a position in Alaunos Therapeutics in Q3 2015 and held it in 12 quarters.
  • Cambridge Investment Research Advisors's Alaunos Therapeutics position peaked at $300K in Q3 2017.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2022, filed 17 Oct 2022.